Skip to main content

Table 1 Patient Baseline Demographic and Clinical Characteristics

From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Characteristic Patient
  No %
Sex   
   Male 26 56.5
   Female 20 43.5
Age, years   
   Median 51  
   Range 23-68  
ECOG performance status   
   0 8 17.4
   1 36 78.3
   2 2 4.3
Prior Therapy 46  
   Chemotherapy (including cytokine and TKI)   
1 21  
2 10  
≥3 15  
   Radiotherapy 13  
   Surgery 39  
   Other (Endocrine/Intervention) 7  
Measurability of baseline disease   
   Measurable 45 97.8
   Unmeasurable 1 2.1
Primary tumor site   
   Gastrointestinal tract 34 73.9
   Bronchus/Lung 3 6.5
   Breast 3 6.5
   Other 6 13
  1. Abbreviation: ECOG, Eastern Cooperative Oncology Group